ClinicalTrials.gg
CompletedNCT01194245Updated Feb 26, 2019Results posted

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

A Phase 2 interventional study of Insulin lispro and recombinant human hyaluronidase PH20 in Diabetes Mellitus, Type 1, sponsored by Halozyme Therapeutics. Completed at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Halozyme Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 — 3 open to participants now, 3 under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 1.

Enrollment
10th of 69
135 · median 38
Started
2010
with 3 others
Phase 2
7 of 69
none open now
Registered
15th of 69
by date
Lead sponsor
4 of 69
Halozyme Therapeutics

Among the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, this one is the 10th largest by enrollment, is one of 4 that started in 2010, is one of 7 in phase 2, and was the 15th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing Insulin Lispro in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in basal-bolus therapy.

Read the detailed description

Criteria for randomization into the study included 1) fasting blood glucose and predinner glucose values in the range of 70 to 140 milligrams per deciliter (mg/dL) approximately 60% of the time for 7 days prior to randomization 2) 90 minute or 2-hour postprandial blood glucose \<220 mg/dL approximately 70% of the time for 7 days prior to randomization and 3) successfully completed 3 days of 10-point glucose monitoring and have at least 4 self-monitored blood glucose values on all non-10-point monitoring days. Participants that did not meet 1 or more of these criteria during a 4- to 6-week Titration Period were not randomized.

03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Type 1 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged ≥18 years
  • Type 1 Diabetes Mellitus (T1DM) treated with insulin for ≥12 months
  • (BMI) 18.0 to 40.0 kilograms per square meter (kg/m\^2).
  • (HbA1C) level 6.7% to 8.2%, inclusive
  • Fasting C-peptide \<0.6 nanograms per milliliter (ng/mL)
  • Willingness to use twice daily (BID) insulin glargine as basal insulin for the duration of the study
  • Willingness to avoid use of an insulin infusion pump or unblinded continuous glucose monitoring (CGM) during the study

Exclusion criteria

Exclusion Criteria:

  • Known or suspected allergy to any component of any of the study drugs
  • Use of pramlintide within 30 days of Screening
  • Use of drugs during the study or within 30 days of Screening (such as or antimetabolites) that could interfere with the interpretation of study results or are known to cause interference with insulin action, glucose utilization, or recovery from hypoglycemia
  • Recurrent severe hypoglycemia (more than 2 episodes over the last 6 months) or hypoglycemic unawareness, as judged by the Investigator
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Lispro-PH20 / Insulin Lispro

    All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually. Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period. Lispro-PH20 (Treatment A): 100 U/mL insulin lispro with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine.

    Drug: Insulin lispro · Drug: recombinant human hyaluronidase PH20 · Drug: Insulin glulisine · Drug: Insulin glargine

  • Experimental
    Aspart-PH20 / Insulin Lispro

    All enrolled participants underwent a titration period of 4-6 weeks in which they received 100 units per milliliter (U/mL) insulin glulisine, injected subcutaneously (SC), pre-meals, with doses titrated to each participant individually. Next participants were randomly assigned to 1 of 2 study treatments (Treatment A or B) for the first of two, 3-month treatment cycles. Each participant then received the second treatment for the second cycle with no washout period. Aspart-PH20 (Treatment A): 100 U/mL insulin aspart with 5.0 micrograms per milliliter (µg/mL) recombinant human hyaluronidase PH20, injected SC, pre-meals, with doses titrated to each participant individually Insulin Lispro (Treatment B): 100 U/mL insulin lispro, injected SC, pre-meals, with doses titrated to each participant individually Throughout the study, participants requiring basal insulin used twice daily SC injections of 100 U/mL insulin glargine.

    Drug: Insulin lispro · Drug: recombinant human hyaluronidase PH20 · Drug: Insulin aspart · Drug: Insulin glulisine · Drug: Insulin glargine

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period

    Glycosylated hemoglobin A1C (HBA1c) levels were measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). Least Squares (LS) means were calculated from mixed effects linear models with treatment (Lispro, Aspart), recombinant human hyaluronidase PH20 (rHuPH20; yes, no), and treatment sequence as fixed effects and participant within treatment sequence as a random effect.

    Time frame: Baseline, Week 12 and Week 24

Secondary outcomes

  1. Mean Daily Insulin Dose

    Prandial insulin doses were recorded during 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). The mean daily insulin dose over the 3 days during each treatment period is presented. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

    Time frame: Week 10 and Week 22

  2. Percentage of Participants Meeting Glucose Targets

    Participants were instructed to monitor their blood glucose levels a minimum of 4 times per day on all non-10-point glucose monitoring days. The number of participants meeting 90-minute postprandial plasma glucose (PPG) targets of \<140 and \<180 milligrams per deciliter (mg/dL) for at least 2/3 of values during non-10-point glucose monitoring days was recorded. The percentage was calculated by dividing the number of participants with values meeting the specified target at least 2/3 of the time by the total number of participants analyzed, multiplied by 100. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

    Time frame: Baseline through Week 24, excluding 10-point glucose monitoring days

  3. Rates of Hypoglycemia at the End of Each Treatment Period

    Overall rates of hypoglycemia (blood glucose ≤70 milligrams per deciliter \[mg/dL\] and \<56 mg/dL) were calculated based on 4 weeks of observation for each treatment period. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Week 12 and Week 24

  4. Change From Baseline in Body Weight at the End of Each Treatment Period

    Body weight was measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

    Time frame: Baseline, Week 12 and Week 24

  5. Mean Daily Postprandial Glucose (PPG) Excursions

    Participants performed 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). Mean daily postprandial plasma glucose (PPG) excursions (referring to the change in blood glucose levels from before to after a meal) during 10-point glucose monitoring for breakfast, lunch, and dinner are presented. Data were collected 1 and 2 hours (hr) after each meal for 3 days and the means of each excursion are presented.

    Time frame: Week 10 and Week 22

07

Results

Posted Aug 19, 2014

Participant flow

Titration Period (4 to 6 Weeks)
Participant flow — Titration Period (4 to 6 Weeks)
MilestoneAll Enrolled ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20
Started1350000
Completed1170000
Not completed180000
Withdrew: Withdrawal by subject50000
Withdrew: Physician decision30000
Withdrew: Titration failure30000
Withdrew: Did not meet randomization criteria70000
Treatment Period 1 (Weeks 0 to 12)
Participant flow — Treatment Period 1 (Weeks 0 to 12)
MilestoneAll Enrolled ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20
Started029283030
Received at least 1 dose of study drug029283030
Completed029272928
Not completed00112
Withdrew: Lost to follow-up00001
Withdrew: Withdrawal by subject00111
Treatment Period 2 (Weeks 12 to 24)
Participant flow — Treatment Period 2 (Weeks 12 to 24)
MilestoneAll Enrolled ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20
Started029272928
Completed029272928
Not completed00000

Outcome measures

SecondaryMean Daily Insulin Dose

Prandial insulin doses were recorded during 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). The mean daily insulin dose over the 3 days during each treatment period is presented. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

Time frame:
Week 10 and Week 22
Reported as:
Mean · units (U)
Mean Daily Insulin Dose
units (U)Analog-PH20Insulin Lispro
Mean Daily Insulin Dose54.28 ± 27.07156.05 ± 27.243
SecondaryPercentage of Participants Meeting Glucose Targets

Participants were instructed to monitor their blood glucose levels a minimum of 4 times per day on all non-10-point glucose monitoring days. The number of participants meeting 90-minute postprandial plasma glucose (PPG) targets of \<140 and \<180 milligrams per deciliter (mg/dL) for at least 2/3 of values during non-10-point glucose monitoring days was recorded. The percentage was calculated by dividing the number of participants with values meeting the specified target at least 2/3 of the time by the total number of participants analyzed, multiplied by 100. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

Time frame:
Baseline through Week 24, excluding 10-point glucose monitoring days
Reported as:
Number · percentage of participants
Percentage of Participants Meeting Glucose Targets
percentage of participantsAnalog-PH20Insulin Lispro
PPG <140 mg/dL for all meals15.08.8
PPG <140 mg/dL for breakfast21.410.6
PPG <180 mg/dL for all meals69.959.3
PPG <180 mg/dL for breakfast70.554.0
SecondaryRates of Hypoglycemia at the End of Each Treatment Period

Overall rates of hypoglycemia (blood glucose ≤70 milligrams per deciliter \[mg/dL\] and \<56 mg/dL) were calculated based on 4 weeks of observation for each treatment period. Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Week 12 and Week 24
Reported as:
Number · events per participant per month
Rates of Hypoglycemia at the End of Each Treatment Period
events per participant per monthAnalog-PH20Insulin Lispro
≤70 mg/dL18.9619.91
<56 mg/dL7.508.05
PrimaryChange From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period

Glycosylated hemoglobin A1C (HBA1c) levels were measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data are presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts). Least Squares (LS) means were calculated from mixed effects linear models with treatment (Lispro, Aspart), recombinant human hyaluronidase PH20 (rHuPH20; yes, no), and treatment sequence as fixed effects and participant within treatment sequence as a random effect.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · percentage of hemoglobin A1C
Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period
percentage of hemoglobin A1CAnalog-PH20Insulin Lispro
Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment Period-0.14 ± 0.415-0.19 ± 0.440
Statistical analysis
  • Analog-PH20 vs Insulin Lispro · Mixed Models Analysis · p = 0.2878 · Ls means difference: 0.05 · 95% CI -0.05 to 0.15
SecondaryChange From Baseline in Body Weight at the End of Each Treatment Period

Body weight was measured at baseline (Week 0) and at the end of each treatment period (Week 12 and Week 24). Data is presented by combined treatment group (Lispro-PH20 + Aspart-PH20 = Analog-PH20) and combined comparator drug (Insulin Lispro from both cohorts).

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · pounds (lbs)
Change From Baseline in Body Weight at the End of Each Treatment Period
pounds (lbs)Analog-PH20Insulin Lispro
Change From Baseline in Body Weight at the End of Each Treatment Period-0.25 ± 5.7020.10 ± 4.601
SecondaryMean Daily Postprandial Glucose (PPG) Excursions

Participants performed 10-point glucose monitoring for a total of 3 days during each treatment period (3 days during Week 10 of Treatment Period 1 and 3 days during Week 22 of Treatment Period 2). Mean daily postprandial plasma glucose (PPG) excursions (referring to the change in blood glucose levels from before to after a meal) during 10-point glucose monitoring for breakfast, lunch, and dinner are presented. Data were collected 1 and 2 hours (hr) after each meal for 3 days and the means of each excursion are presented.

Time frame:
Week 10 and Week 22
Reported as:
Mean · milligrams per deciliter (mg/dL)
Mean Daily Postprandial Glucose (PPG) Excursions
milligrams per deciliter (mg/dL)Analog-PH20Insulin Lispro
1-hr breakfast excursion18.85 ± 48.34827.46 ± 43.938
2-hr breakfast excursion-5.63 ± 52.6577.08 ± 56.997
1-hr lunch excursion16.26 ± 46.52426.25 ± 39.070
2-hr lunch excursion10.68 ± 53.78720.77 ± 47.005
1-hr dinner excursion-0.31 ± 41.3684.47 ± 52.986
2-hr dinner excursion-5.13 ± 46.956-5.16 ± 54.309

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Titration Period (All Enrolled Participants)—2/135 (1.5%)48/135 (35.6%)
Lispro-PH20 Treatment Period—0/56 (0%)34/56 (60.7%)
Insulin Lispro (Lispro-PH20 Cohort) Treatment Period—1/57 (1.8%)29/57 (50.9%)
Aspart-PH20 Treatment Period—0/58 (0%)27/58 (46.6%)
Insulin Lispro (Aspart-PH20 Cohort) Treatment Period—1/59 (1.7%)30/59 (50.8%)
Most frequent serious events
Most frequent serious events
EventTitration Period (All Enrolled Participants)Lispro-PH20 Treatment PeriodInsulin Lispro (Lispro-PH20 Cohort) Treatment PeriodAspart-PH20 Treatment PeriodInsulin Lispro (Aspart-PH20 Cohort) Treatment Period
HypoglycaemiaMetabolism and nutrition disorders1/1350/561/570/581/59
PericarditisCardiac disorders1/1350/560/570/580/59
Most frequent other events
Showing 10 of 135
Most frequent other events
EventTitration Period (All Enrolled Participants)Lispro-PH20 Treatment PeriodInsulin Lispro (Lispro-PH20 Cohort) Treatment PeriodAspart-PH20 Treatment PeriodInsulin Lispro (Aspart-PH20 Cohort) Treatment Period
NasopharyngitisInfections and infestations8/1358/568/578/586/59
Upper respiratory tract infectionInfections and infestations8/1357/563/572/583/59
SinusitisInfections and infestations5/1352/563/575/582/59
HeadacheNervous system disorders2/1351/561/574/581/59
PyrexiaGeneral disorders2/1351/563/570/580/59
CoughRespiratory, thoracic and mediastinal disorders0/1350/560/573/580/59
Gastroenteritis viralInfections and infestations1/1351/562/572/583/59
NauseaGastrointestinal disorders2/1351/560/571/583/59
DysmenorrhoeaReproductive system and breast disorders0/610/261/260/280/29
Back painMusculoskeletal and connective tissue disorders2/1352/560/570/580/59

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Non-randomized ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20Total
Mean34.8 ± 11.7144.6 ± 14.5645.7 ± 14.9442.8 ± 14.1342.5 ± 14.7042.6 ± 14.41
Sex: Female, Male
Sex: Female, Male(Participants)Non-randomized ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20Total
Female61313141561
Male121615161574
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Non-randomized ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20Total
American Indian or Alaska Native000000
Asian100001
Native Hawaiian or Other Pacific Islander000000
Black or African American001023
White1727273028129
More than one race020002
Unknown or Not Reported000000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Non-randomized ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20Total
Hispanic or Latino4122110
Not Hispanic or Latino1428262829125
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Non-randomized ParticipantsLispro-PH20 First, Then Insulin LisproInsulin Lispro First, Then Lispro-PH20Aspart-PH20 First, Then Insulin LisproInsulin Lispro First, Then Aspart-PH20Total
United States1829283030135
08

Study locations

19 sites
  • AMCR Institute, Inc.
    Escondido, California 92026, United States
  • Scripps Whittier Diabetes Institute
    La Jolla, California 92037, United States
  • Mills-Peninsula Health Services
    San Mateo, California 94401, United States
  • Barbara Davis Center for Childhood Diabetes
    Aurora, Colorado 80045, United States
  • Center for Diabetes and Endocrine Care
    Hollywood, Florida 33021, United States
  • Diabetes Research Institute
    Miami, Florida 33136, United States
  • Rocky Mountain Diabetes and Osteoporosis Center
    Idaho Falls, Idaho 83404, United States
  • Mid-America Diabetes Associates
    Wichita, Kansas 67211, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Medstar Research Institute
    Hyattsville, Maryland 20782, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • Mercury Street Medical
    Butte, Montana 59701, United States
  • Desert Endocrinology
    Henderson, Nevada 89052, United States
  • UT Southwestern Medical Center at Dallas
    Dallas, Texas 75390, United States
  • Texas Diabetes and Endocrinology
    Round Rock, Texas 78681, United States
  • Cetero Research-San Antonio
    San Antonio, Texas 78229, United States
  • West Olympia Internal Medicine
    Olympia, Washington 98502, United States
  • University of Washington School of Medicine
    Seattle, Washington 98105, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2010
First posted
Sep 2, 2010
Start
Aug 2010
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Aug 19, 2014
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01194245
Responsible party
Sponsor
First posted
Sep 2, 2010
Start date
Aug 2010
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Aug 19, 2014
Last update
Feb 26, 2019

Study contacts

Douglas Muchmore, M.D.
study director · Halozyme Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Lispro · Hyaluronidase (human recombinant)

Start the discussion